CASP3 and plasma cell myeloma: SRT1720 has been shown to decrease the viability of multiple myeloma cells through caspase-3 mediated apoptosis28 and pancreatic cancer cells through a SIRT1-lysosomal-cell death pathway.29 SRT1720 appears to have a mainly protective effect in non-tumor cells.